Literature DB >> 19184364

Thrombogenesis in atrial fibrillation contributing mechanisms and natural history.

Richard C Becker1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19184364     DOI: 10.1007/s11239-009-0307-5

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  16 in total

1.  Circulating tissue factor accumulates in thrombi, but not in hemostatic plugs.

Authors:  M Hoffman; H C Whinna; D M Monroe
Journal:  J Thromb Haemost       Date:  2006-09       Impact factor: 5.824

Review 2.  Microparticles in vascular diseases.

Authors:  Françoise Dignat George
Journal:  Thromb Res       Date:  2008       Impact factor: 3.944

3.  Differential transcriptional activation of matrix metalloproteinase-2 and membrane type-1 matrix metalloproteinase by experimental deep venous thrombosis and thrombin.

Authors:  Sia Dahi; Jackie G Lee; David H Lovett; Rajabrata Sarkar
Journal:  J Vasc Surg       Date:  2005-09       Impact factor: 4.268

4.  Thrombin and its protease-activated receptor-1 (PAR1) participate in the endothelial-mesenchymal transdifferentiation process.

Authors:  Enrique Archiniegas; Carmen Yudith Neves; Daniel Candelle; José E Cardier
Journal:  DNA Cell Biol       Date:  2004-12       Impact factor: 3.311

5.  Structural remodeling of the left atrial appendage in patients with chronic non-valvular atrial fibrillation: Implications for thrombus formation, systemic embolism, and assessment by transesophageal echocardiography.

Authors:  J Shirani; J Alaeddini
Journal:  Cardiovasc Pathol       Date:  2000 Mar-Apr       Impact factor: 2.185

6.  Segregation of platelet aggregatory and procoagulant microdomains in thrombus formation: regulation by transient integrin activation.

Authors:  Imke C A Munnix; Marijke J E Kuijpers; Jocelyn Auger; Christella M L G D Thomassen; Peter Panizzi; Marc A M van Zandvoort; Jan Rosing; Paul E Bock; Steve P Watson; Johan W M Heemskerk
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-08-30       Impact factor: 8.311

7.  Procoagulant properties of flow fields in stenotic and expansive orifices.

Authors:  Anna M Fallon; Lakshmi Prasad Dasi; Ulla M Marzec; Stephen R Hanson; Ajit P Yoganathan
Journal:  Ann Biomed Eng       Date:  2007-11-06       Impact factor: 3.934

8.  The serum- and glucocorticoid-inducible kinase Sgk-1 is involved in pulmonary vascular remodeling: role in redox-sensitive regulation of tissue factor by thrombin.

Authors:  Rachida S BelAiba; Talija Djordjevic; Steve Bonello; Ferruh Artunc; Florian Lang; John Hess; Agnes Görlach
Journal:  Circ Res       Date:  2006-02-16       Impact factor: 17.367

9.  Effect of atrial fibrillation on hematopoietic progenitor cells: a novel pathophysiological role of the atrial natriuretic peptide?

Authors:  Andreas Goette; Kathleen Jentsch-Ullrich; Uwe Lendeckel; Christoph Röcken; Mahmood Agbaria; Angelo Auricchio; Martin Mohren; Astrid Franke; Helmut U Klein
Journal:  Circulation       Date:  2003-11-10       Impact factor: 29.690

10.  Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).

Authors:  Jeff S Healey; Robert G Hart; Janice Pogue; Marc A Pfeffer; Stefan H Hohnloser; Raffaele De Caterina; Greg Flaker; Salim Yusuf; Stuart J Connolly
Journal:  Stroke       Date:  2008-03-06       Impact factor: 7.914

View more
  4 in total

1.  Urgent monitoring of direct oral anticoagulants in patients with atrial fibrillation: a tentative approach based on routine laboratory tests.

Authors:  Giuseppe Lippi; Diego Ardissino; Roberto Quintavalla; Gianfranco Cervellin
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

2.  Recent Advances in Percutaneous Cardioscopy.

Authors:  Yasumi Uchida
Journal:  Curr Cardiovasc Imaging Rep       Date:  2011-05-12

Review 3.  New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders.

Authors:  Ola E Dahl
Journal:  Vasc Health Risk Manag       Date:  2012-01-25

4.  An illustrative case of endocardial fibroelastosis and recalcitrant intracardiac thrombosis: a case report.

Authors:  Denizhan Ozdemir; Isabel Oliva Cortopassi; Robert Lawrence McNamara
Journal:  Thromb J       Date:  2019-06-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.